Clinical Trial Update: ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases [Phase 3]

View source ↗

Summary

A Phase 3 trial of ZOMETA (zoledronic acid) for prevention of bone metastases in prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Central European Cooperative Oncology Group | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED